Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 039, 7617-7619 [2015-02801]
Download as PDF
Federal Register / Vol. 80, No. 28 / Wednesday, February 11, 2015 / Notices
addition to input generated through this
public meeting, FDA is interested in
receiving patient input addressing these
questions through written comments,
which can be submitted to the public
docket (see ADDRESSES).
tkelley on DSK3SPTVN1PROD with NOTICES
Topic 1: Disease Symptoms and Daily
Impacts That Matter Most to Patients
• Have you received a diagnosis of a
functional GI disorder from a health
care provider? If so, please state the
condition.
• Of all the symptoms that you
experience because of your condition,
which one to three symptoms have the
most significant impact on your life?
(Examples may include pain, bloating,
constipation, vomiting)
• Are there specific activities that are
important to you but that you cannot do
at all or as fully as you would like
because of your condition? (Examples of
activities may include sleeping through
the night, daily hygiene)
Æ How do your symptoms and their
negative impacts affect your daily life
on the best days? On the worst days?
• How has your condition and its
symptoms changed over time?
Æ Do your symptoms come and go or
are they ongoing? If so, do you know of
anything that worsens your symptoms?
• What worries you most about your
condition?
Topic 2: Patients’ Perspectives on
Current Approaches To Treating
Functional GI Disorders
• What are you currently doing to
help treat your condition or its
symptoms? (Examples may include
prescription medicines, over-thecounter products, and other therapies
including nondrug therapies such as
diet modification.)
Æ What specific symptoms do your
treatments address?
Æ How has your treatment regimen
changed over time, and why?
• How well does your current
treatment regimen treat the most
significant symptoms of your disease?
Æ How well do these treatments stop
or slow the progression of your
condition?
Æ How well do these therapies
improve your ability to do specific
activities that are important to you in
your daily life?
Æ How well have these treatments
worked for you as your condition has
changed over time?
• What are the most significant
downsides to your current treatments,
and how do they affect your daily life?
(Examples of downsides may include
bothersome side effects, going to the
hospital for treatment, restrictions on
driving, etc.)
VerDate Sep<11>2014
17:07 Feb 10, 2015
Jkt 235001
• Assuming there is no complete cure
for your condition, what specific things
would you look for in an ideal treatment
for your condition?
Dated: February 5, 2015.
Leslie Kux,
Associate Commissioner for Policy.
B. Meeting Attendance and
Participation
BILLING CODE 4164–01–P
If you wish to attend this meeting,
visit https://pfddfunctionalgi
disorders.eventbrite.com. Please register
by May 1, 2015. If you are unable to
attend the meeting in person, you can
register to view a live Webcast of the
meeting. You will be asked to indicate
in your registration if you plan to attend
in person or via the Webcast. Seating
will be limited, so early registration is
recommended. Registration is free and
will be on a first-come, first-served
basis. However, FDA may limit the
number of participants from each
organization based on space limitations.
Registrants will receive confirmation
once they have been accepted. Onsite
registration on the day of the meeting
will be based on space availability. If
you need special accommodations
because of a disability, please contact
Pegah Mariani (see FOR FURTHER
INFORMATION CONTACT) at least 7 days
before the meeting.
Patients who are interested in
presenting comments as part of the
initial panel discussions will be asked
to indicate in their registration which
topic(s) they wish to address. These
patients also must send to
PatientFocused@fda.hhs.gov a brief
summary of responses to the topic
questions by April 24, 2015. Panelists
will be notified of their selection
approximately 7 days before the public
meeting. We will try to accommodate all
patients and patient stakeholders who
wish to speak, either through the panel
discussion or audience participation;
however, the duration of comments may
be limited by time constraints.
7617
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
III. Comments
Regardless of whether you attend the
public meeting, you can submit
electronic or written responses to the
questions pertaining to Topics 1 and 2
to the public docket (see ADDRESSES) by
July 13, 2015. Received comments may
be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday, and will be
posted to the docket at https://
www.regulations.gov.
IV. Transcripts
As soon as a transcript is available,
FDA will post it at https://www.fda.gov/
ForIndustry/UserFees/Prescription
DrugUserFee/ucm430885.htm.
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
[FR Doc. 2015–02804 Filed 2–10–15; 8:45 am]
Food and Drug Administration
[Docket No. FDA–2004–N–0451]
Food and Drug Administration
Modernization Act of 1997:
Modifications to the List of Recognized
Standards, Recognition List Number:
039
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing a
publication containing modifications
the Agency is making to the list of
standards FDA recognizes for use in
premarket reviews (‘‘FDA Recognized
Consensus Standards’’). Specifically,
this publication announces the addition
of a list of recognized standards that are
relevant to safety considerations to
mitigate the risks of misconnections
with small-bore connectors intended for
enteral applications. This publication,
entitled ‘‘Modifications to the List of
Recognized Standards, Recognition List
Number: 039’’ (‘‘Recognition List
Number: 039’’), will assist
manufacturers who elect to declare
conformity with consensus standards to
meet certain requirements for medical
devices.
SUMMARY:
Submit either electronic or
written comments concerning this
document at any time. See section VI for
the effective date of the recognition of
standards announced in this document.
ADDRESSES: An electronic copy of
Recognition List Number: 039 is
available on the Internet at https://
www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
Standards/ucm123792.htm. See section
V for electronic access to the searchable
database for the current list of FDA
recognized consensus standards,
including Recognition List Number: 039
modifications and other standards
related information.
Submit written requests for single
copies of the document entitled
‘‘Modifications to the List of Recognized
Standards, Recognition List Number:
039’’ to the Division of Industry and
Consumer Education, Center for Devices
and Radiological Health, Food and Drug
DATES:
E:\FR\FM\11FEN1.SGM
11FEN1
7618
Federal Register / Vol. 80, No. 28 / Wednesday, February 11, 2015 / Notices
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 4613, Silver Spring,
MD 20993–0002. Send two selfaddressed adhesive labels to assist that
office in processing your request, or fax
your request to 301–847–8149.
Submit electronic comments on this
document to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. Identify
comments with the docket number
found in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Scott A. Colburn, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 3632, Silver Spring,
MD 20993, 301–796–6287, standards@
cdrh.fda.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Section 204 of the Food and Drug
Administration Modernization Act of
1997 (Pub. L. 105–115) amended section
514 of the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) (21 U.S.C.
360d). Amended section 514 allows
FDA to recognize consensus standards
developed by international and national
organizations for use in satisfying
portions of device premarket review
submissions or other requirements.
In a notice published in the Federal
Register of February 25, 1998 (63 FR
9561), FDA announced the availability
of a guidance entitled ‘‘Recognition and
Use of Consensus Standards.’’ The
notice described how we would
implement our standard recognition
program and provided the initial list of
recognized standards.
Modifications to the initial list of
recognized standards, as published in
the Federal Register, can be accessed at
https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
Standards/ucm123792.htm.
These notices describe the addition,
withdrawal, and revision of certain
standards recognized by FDA. The
Agency maintains HTML and PDF
versions of the list of FDA Recognized
Consensus Standards. Both versions are
publicly accessible at the Agency’s
Internet site. See section V of this
document for electronic access
information. Interested persons should
review the supplementary information
sheet for the standard to understand
fully the extent to which FDA
recognizes the standard.
II. Listing of New Entries
In table 1 of this document, FDA
provides the listing of new entries and
consensus standards added as
modifications to the list of recognized
standards under Recognition List
Number: 039. Specifically, this
publication announces the addition of a
list of recognized standards that are
relevant to safety considerations to
mitigate the risks of misconnections
with small-bore connectors intended for
enteral applications. Elsewhere in this
issue of the Federal Register, we are
publishing a notice of availability of the
guidance document entitled ‘‘Safety
Considerations to Mitigate the Risks of
Misconnections With Small-Bore
Connectors Intended for Enteral
Applications.’’ This guidance provides
recommendations to manufacturers
regarding the expectations for design
and testing of small-bore connectors
intended for enteral applications
(‘‘enteral devices’’). FDA is making
these recommendations to reduce the
risk of unintended connections between
enteral and non-enteral devices.
TABLE 1—NEW ENTRIES TO THE LIST OF RECOGNIZED STANDARDS
Title of standard 1
Recognition No.
Reference No. and date
A. General I (Quality Systems/Risk Management)
5–93 ................................................
5–94 ................................................
tkelley on DSK3SPTVN1PROD with NOTICES
1 All
Small-bore connectors for liquids and gases in healthcare applications—Part 3: Connectors for enteral applications.
Small-bore connectors for liquids and gases in healthcare applications—Part 20: Common test methods.
AAMI/CN3:2014 (PS).
AAMI/CN20:2014 (PS).
standard titles in this table conform to the style requirements of the respective organizations.
III. List of Recognized Standards
FDA maintains the Agency’s current
list of FDA recognized consensus
standards in a searchable database that
may be accessed directly at FDA’s
Internet site at https://www.access
data.fda.gov/scripts/cdrh/cfdocs/
cfStandards/search.cfm. FDA will
incorporate the modifications and
revisions described in this notice into
the database and, upon publication in
the Federal Register, this recognition of
consensus standards will be effective.
FDA will announce additional
modifications and revisions to the list of
recognized consensus standards, as
needed, in the Federal Register once a
year, or more often, if necessary.
Beginning with Recognition List 033,
FDA no longer announces minor
revisions to the list of recognized
consensus standards such as technical
contact person, devices affected,
VerDate Sep<11>2014
17:07 Feb 10, 2015
Jkt 235001
processes affected, Code of Federal
Regulations citations, and product
codes.
IV. Recommendation of Standards for
Recognition by FDA
identification of the testing or
performance or other characteristics of
the device(s) that would be addressed
by a declaration of conformity.
V. Electronic Access
Any person may recommend
consensus standards as candidates for
recognition under section 514 of the
FD&C Act by submitting such
recommendations, with reasons for the
recommendation, to standards@
cdrh.fda.gov. To be properly considered,
such recommendations should contain,
at a minimum, the following
information: (1) Title of the standard, (2)
any reference number and date, (3)
name and address of the national or
international standards development
organization, (4) a proposed list of
devices for which a declaration of
conformity to this standard should
routinely apply, and (5) a brief
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
You may obtain a copy of ‘‘Guidance
on the Recognition and Use of
Consensus Standards’’ by using the
Internet. The Center for Devices and
Radiological Health (CDRH) maintains a
site on the Internet for easy access to
information including text, graphics,
and files that you may download to a
personal computer with access to the
Internet. Updated on a regular basis, the
CDRH home page, https://www.fda.gov/
MedicalDevices, includes a link to
standards-related documents including
the guidance and the current list of
recognized standards. After publication
in the Federal Register, this notice
announcing ‘‘Modification to the List of
E:\FR\FM\11FEN1.SGM
11FEN1
7619
Federal Register / Vol. 80, No. 28 / Wednesday, February 11, 2015 / Notices
Recognized Standards, Recognition List
Number: 039’’ will be available https://
www.fda.gov/MedicalDevices/Device
RegulationandGuidance/Standards/
ucm123792.htm.
You may access ‘‘Guidance on the
Recognition and Use of Consensus
Standards,’’ and the searchable database
for ‘‘FDA Recognized Consensus
Standards’’ at https://www.fda.gov/
MedicalDevices/DeviceRegulationand
Guidance/Standards.
VI. Submission of Comments and
Effective Date
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov. FDA will consider
any comments received in determining
whether to amend the current listing of
modifications to the list of recognized
standards, Recognition List Number:
039. These modifications to the list of
recognized standards are effective upon
publication of this notice in the Federal
Register.
Dated: February 5, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–02801 Filed 2–10–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment
Request; Population Assessment of
Tobacco and Health (PATH) Study
In compliance with the
requirement of Section 3506(c)(2)(A) of
SUMMARY:
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Institute on Drug Abuse
(NIDA), National Institutes of Health
(NIH), will publish periodic summaries
of proposed projects to be submitted to
the Office of Management and Budget
(OMB) for review and approval.
Written comments and/or suggestions
from the public and affected agencies
are invited on one or more of the
following points: (1) Whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
The quality, utility, and clarity of the
information to be collected; and (4) The
approaches used to minimize the
burden of the collection of information
on those who are to respond, including
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
To Submit Comments and for Further
Information: To obtain a copy of the
data collection plans and instruments,
submit comments in writing or request
more information on the proposed
project, contact: Kevin P. Conway,
Ph.D., Deputy Director, Division of
Epidemiology, Services, and Prevention
Research, National Institute on Drug
Abuse, 6001 Executive Boulevard, Room
5185; or call non-toll-free number (301)–
443–8755; or Email your request,
including your address to:
PATHprojectofficer@mail.nih.gov.
Formal requests for additional plans and
instruments must be requested in
writing.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Proposed Collection: Population
Assessment of Tobacco and Health
(PATH) Study—Third Wave of Data
Collection—0925–0664–REVISION—
National Institutes of Health (NIH),
National Institute on Drug Abuse
(NIDA), in partnership with the Food
and Drug Administration (FDA).
Need and Use of Information
Collection: This is a revision request
(OMB 0925–0664, Exp. Date 9/30/2016)
for the Population Assessment of
Tobacco and Health (PATH) Study to
conduct the third wave of data
collection. The PATH Study is a large
national longitudinal cohort study on
tobacco use behavior and health among
the U.S. household population of adults
age 18 and older and youth ages 12 to
17. The PATH Study conducts annual
interviews and collects biospecimens
from adults to help inform the
development, implementation, and
evaluation of tobacco-product
regulations by FDA in meeting its
mission under the Family Smoking
Prevention and Tobacco Control Act
(TCA) to regulate tobacco products,
including tobacco-product advertising,
labeling, marketing, constituents,
ingredients, and additives. The
longitudinal design of the PATH Study
provides it with the capacity to measure
and report within-person changes and
between-person differences in tobacco
product use behaviors and health effects
within the cohort over time. These data
will help to inform regulatory decisions
and actions by FDA and FDA’s
evaluations of associations between its
regulations and tobacco use behaviors
and health indicators in the population.
OMB approval is requested for 3
years. There are no capital, operating, or
maintenance costs to report. There are
no costs to respondents other than their
time. The total estimated annualized
burden hours are 53,459.
ESTIMATED ANNUALIZED BURDEN HOURS
tkelley on DSK3SPTVN1PROD with NOTICES
Adults—Adult respondents at Wave 1 or Wave 2—Extended
Interview .......................................................................................
Adults—Wave 1 youth respondents who age up to adult cohort at
Wave 3—Consent for Extended Interview ...................................
Adults—Wave 1 youth respondents who age up to adult cohort at
Wave 3—Extended Interview .......................................................
Adults—Wave 1 youth respondents who age up to adult cohort at
Wave 3—Consent for Biological Samples ...................................
Adults—Biospecimen Collection: Urine ...........................................
VerDate Sep<11>2014
17:07 Feb 10, 2015
Jkt 235001
PO 00000
Number of
responses per
respondent
Number of
respondents
Type of respondent and instrument
Frm 00056
Fmt 4703
Average burden
per response
(in hours)
Total annual
burden hours
25,692
1
1
25,692
2,317
1
4/60
154
1,738
1
68/60
1,970
1,738
13,703
1
1
5/60
10/60
145
2,284
Sfmt 4703
E:\FR\FM\11FEN1.SGM
11FEN1
Agencies
[Federal Register Volume 80, Number 28 (Wednesday, February 11, 2015)]
[Notices]
[Pages 7617-7619]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-02801]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2004-N-0451]
Food and Drug Administration Modernization Act of 1997:
Modifications to the List of Recognized Standards, Recognition List
Number: 039
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing a
publication containing modifications the Agency is making to the list
of standards FDA recognizes for use in premarket reviews (``FDA
Recognized Consensus Standards''). Specifically, this publication
announces the addition of a list of recognized standards that are
relevant to safety considerations to mitigate the risks of
misconnections with small-bore connectors intended for enteral
applications. This publication, entitled ``Modifications to the List of
Recognized Standards, Recognition List Number: 039'' (``Recognition
List Number: 039''), will assist manufacturers who elect to declare
conformity with consensus standards to meet certain requirements for
medical devices.
DATES: Submit either electronic or written comments concerning this
document at any time. See section VI for the effective date of the
recognition of standards announced in this document.
ADDRESSES: An electronic copy of Recognition List Number: 039 is
available on the Internet at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Standards/ucm123792.htm. See section V for
electronic access to the searchable database for the current list of
FDA recognized consensus standards, including Recognition List Number:
039 modifications and other standards related information.
Submit written requests for single copies of the document entitled
``Modifications to the List of Recognized Standards, Recognition List
Number: 039'' to the Division of Industry and Consumer Education,
Center for Devices and Radiological Health, Food and Drug
[[Page 7618]]
Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 4613, Silver
Spring, MD 20993-0002. Send two self-addressed adhesive labels to
assist that office in processing your request, or fax your request to
301-847-8149.
Submit electronic comments on this document to https://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852. Identify comments with the docket number
found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Scott A. Colburn, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 3632, Silver Spring, MD 20993, 301-796-
6287, standards@cdrh.fda.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Section 204 of the Food and Drug Administration Modernization Act
of 1997 (Pub. L. 105-115) amended section 514 of the Federal Food,
Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 360d). Amended section
514 allows FDA to recognize consensus standards developed by
international and national organizations for use in satisfying portions
of device premarket review submissions or other requirements.
In a notice published in the Federal Register of February 25, 1998
(63 FR 9561), FDA announced the availability of a guidance entitled
``Recognition and Use of Consensus Standards.'' The notice described
how we would implement our standard recognition program and provided
the initial list of recognized standards.
Modifications to the initial list of recognized standards, as
published in the Federal Register, can be accessed at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Standards/ucm123792.htm.
These notices describe the addition, withdrawal, and revision of
certain standards recognized by FDA. The Agency maintains HTML and PDF
versions of the list of FDA Recognized Consensus Standards. Both
versions are publicly accessible at the Agency's Internet site. See
section V of this document for electronic access information.
Interested persons should review the supplementary information sheet
for the standard to understand fully the extent to which FDA recognizes
the standard.
II. Listing of New Entries
In table 1 of this document, FDA provides the listing of new
entries and consensus standards added as modifications to the list of
recognized standards under Recognition List Number: 039. Specifically,
this publication announces the addition of a list of recognized
standards that are relevant to safety considerations to mitigate the
risks of misconnections with small-bore connectors intended for enteral
applications. Elsewhere in this issue of the Federal Register, we are
publishing a notice of availability of the guidance document entitled
``Safety Considerations to Mitigate the Risks of Misconnections With
Small-Bore Connectors Intended for Enteral Applications.'' This
guidance provides recommendations to manufacturers regarding the
expectations for design and testing of small-bore connectors intended
for enteral applications (``enteral devices''). FDA is making these
recommendations to reduce the risk of unintended connections between
enteral and non-enteral devices.
Table 1--New Entries to the List of Recognized Standards
------------------------------------------------------------------------
Reference No.
Recognition No. Title of standard \1\ and date
------------------------------------------------------------------------
A. General I (Quality Systems/Risk Management)
------------------------------------------------------------------------
5-93.......................... Small-bore connectors AAMI/CN3:2014
for liquids and gases (PS).
in healthcare
applications--Part 3:
Connectors for
enteral applications.
5-94.......................... Small-bore connectors AAMI/CN20:2014
for liquids and gases (PS).
in healthcare
applications--Part
20: Common test
methods.
------------------------------------------------------------------------
\1\ All standard titles in this table conform to the style requirements
of the respective organizations.
III. List of Recognized Standards
FDA maintains the Agency's current list of FDA recognized consensus
standards in a searchable database that may be accessed directly at
FDA's Internet site at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm. FDA will incorporate the modifications
and revisions described in this notice into the database and, upon
publication in the Federal Register, this recognition of consensus
standards will be effective. FDA will announce additional modifications
and revisions to the list of recognized consensus standards, as needed,
in the Federal Register once a year, or more often, if necessary.
Beginning with Recognition List 033, FDA no longer announces minor
revisions to the list of recognized consensus standards such as
technical contact person, devices affected, processes affected, Code of
Federal Regulations citations, and product codes.
IV. Recommendation of Standards for Recognition by FDA
Any person may recommend consensus standards as candidates for
recognition under section 514 of the FD&C Act by submitting such
recommendations, with reasons for the recommendation, to
standards@cdrh.fda.gov. To be properly considered, such recommendations
should contain, at a minimum, the following information: (1) Title of
the standard, (2) any reference number and date, (3) name and address
of the national or international standards development organization,
(4) a proposed list of devices for which a declaration of conformity to
this standard should routinely apply, and (5) a brief identification of
the testing or performance or other characteristics of the device(s)
that would be addressed by a declaration of conformity.
V. Electronic Access
You may obtain a copy of ``Guidance on the Recognition and Use of
Consensus Standards'' by using the Internet. The Center for Devices and
Radiological Health (CDRH) maintains a site on the Internet for easy
access to information including text, graphics, and files that you may
download to a personal computer with access to the Internet. Updated on
a regular basis, the CDRH home page, https://www.fda.gov/MedicalDevices,
includes a link to standards-related documents including the guidance
and the current list of recognized standards. After publication in the
Federal Register, this notice announcing ``Modification to the List of
[[Page 7619]]
Recognized Standards, Recognition List Number: 039'' will be available
https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Standards/ucm123792.htm.
You may access ``Guidance on the Recognition and Use of Consensus
Standards,'' and the searchable database for ``FDA Recognized Consensus
Standards'' at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Standards.
VI. Submission of Comments and Effective Date
Interested persons may submit either electronic comments regarding
this document to https://www.regulations.gov or written comments to the
Division of Dockets Management (see ADDRESSES). It is only necessary to
send one set of comments. Identify comments with the docket number
found in brackets in the heading of this document. Received comments
may be seen in the Division of Dockets Management between 9 a.m. and 4
p.m., Monday through Friday, and will be posted to the docket at https://www.regulations.gov. FDA will consider any comments received in
determining whether to amend the current listing of modifications to
the list of recognized standards, Recognition List Number: 039. These
modifications to the list of recognized standards are effective upon
publication of this notice in the Federal Register.
Dated: February 5, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-02801 Filed 2-10-15; 8:45 am]
BILLING CODE 4164-01-P